SCHEMBL1631982

SCHEMBL1631982

Fc1ccc(SC(c2cc(F)ccc2F)c2cc(Cl)ncc2Cl)cc1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
KCNQ3 O43525 1/20 0.32
KCNQ2 O43526 1/20 0.32
PSEN1 P49768 2/20 0.32
PSEN2 P49810 2/20 0.32
APH1B Q8WW43 2/20 0.32
NCSTN Q92542 2/20 0.32
APH1A Q96BI3 2/20 0.32
PSENEN Q9NZ42 2/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1632373 0.96 PSEN1 (0.36) ALDH1A1CYP1A2CYP3A4CYP2C9HPGD
SCHEMBL1634120 0.84 PSEN1 (0.35) ALDH1A1CYP1A2CYP3A4CYP2C9HPGD
SCHEMBL1630928 0.84 PSEN1 (0.35) ALDH1A1CYP1A2CYP3A4CYP2C9HPGD
SCHEMBL1632176 0.81 PSEN1 (0.33) ALDH1A1CYP1A2CYP3A4CYP2C9HPGD
SCHEMBL1632943 0.81 PSEN1 (0.37) ALDH1A1CYP1A2CYP3A4CYP2C9HPGD
SCHEMBL1632265 0.80 CCNT1 (0.41)
SCHEMBL1633549 0.79 DPP4 (0.34) KCNQ3KCNQ2
SCHEMBL27719977 0.79 MAPK14 (0.32) ALDH1A1CYP1A2CYP3A4CYP2C9HPGD
SCHEMBL1631846 0.79 AHR (0.31) ALDH1A1PSEN1PSEN2APH1BNCSTN
SCHEMBL1633221 0.78 ALDH1A1 (0.36) ALDH1A1CYP1A2CYP3A4CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-20060241302-A1 Morpholine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-10-26 US disclosed
EP-1640366-A1 HETEROCYCLIC METHYL SULFONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241302-A1 Morpholine derivatives APP, BACE1, SMS ALDH1A1 3313/4885CYP1A2 431/4885CYP3A4 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.